No trading action warranted. This is a purely administrative AIM Rule 17 disclosure with zero financial or operational impact on HUTCHMED. Monitor for any future filings that might indicate a broader governance concern, but none is present here.
HCM drugs
HCM drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 18 $12.64entry
- T+1 · 3mo ago −0.40%α −0.61% · $12.59
- T+5 · 3mo ago −3.01%α −2.81% · $12.26
- T+20 · 2mo ago +6.49%α +8.23% · $13.46
- T+60 · 6d ago +19.30%α +20.30% · $15.08
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
HUTCHMED filed a routine 6-K disclosing that its Chairman, Dr. Dan Eldar, was formerly a director of S.D. Sight Diagnostics Ltd., which entered insolvency proceedings in Israel. The filing explicitly states the insolvency does not involve HUTCHMED or its operations, and the amount involved (~$1M) is immaterial relative to HUTCHMED's $2.1B market cap. This is a purely administrative AIM Rule disclosure with no financial or operational impact on the company.
Key Facts
- Chairman Dr. Dan Eldar was a director of S.D. Sight Diagnostics from Dec 2018 to Mar 2026.
- S.D. Sight entered insolvency proceedings in Israel; a trustee was appointed on May 28, 2026.
- The amount involved is approximately NIS 3,057,876 (~US$1,019,292).
- Neither S.D. Sight nor Hutchison Water Israel E.P.C Ltd (which holds ~9.98% of S.D. Sight) is part of HUTCHMED.
- The Board states the proceedings have no impact on HUTCHMED's businesses or operations.
Financial Impact
Immaterial, ~$1M insolvency proceeding involving an unrelated third party, less than 0.05% of HUTCHMED's market cap.
Risk Factors
- Reputational risk from association of a director with an insolvent entity, though the company has explicitly disclaimed any operational link.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001648257-26-000051 |
| Document: hcm-20260818xex99d1.htm | 0001648257-26-000051 |
| Document: 0001648257-26-000051-index-headers.html | 0001648257-26-000051 |
| Document: 0001648257-26-000051-index.html | 0001648257-26-000051 |
| Document: 0001648257-26-000051.txt | 0001648257-26-000051 |
Track record
33 reports on HCM
8 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +38.35% at T+60 after the Jun 25, 2026 report. 18 of 23 went positive at some point.
Filters
- Nov 15, 20261d ago Press Release Neutral 4/10 Entry $14.90 Now $14.73 −1.14% settles Feb 12
- Nov 5, 202611d ago 6-K Bullish 5/10 Entry $14.20 Now $14.73 +3.73% settles Feb 3
- Nov 2, 202614d ago 6-K Bullish 6/10 Entry $13.27 Now $14.73 +11.00% settles Jan 29
- Nov 2, 202615d ago Press Release Bullish 6/10 Entry $13.08 Now $14.73 +12.61% settles Feb 1
- Oct 29, 202618d ago 6-K Neutral 4/10 Entry $13.59 Now $14.73 +8.39% settles Jan 27
- Oct 27, 202620d ago 6-K Neutral 2/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 26, 202621d ago 6-K Bullish 6/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202621d ago Press Release Bullish 7/10 Entry $14.27 Now $14.73 +3.22% settles Jan 22
- Oct 26, 202622d ago Press Release Bullish 7/10 Entry $13.80 Now $14.73 +6.74% settles Jan 25
- Oct 21, 202626d ago 6-K Bullish 7/10 Entry $14.37 Now $14.73 +2.51% settles Jan 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers